Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 5/2024

Open Access 01-05-2024 | Ovarian Cancer | Research

Let-7i enhances anti-tumour immunity and suppresses ovarian tumour growth

Authors: Andrew N. Wilkinson, Rui Chen, Elaina Coleborn, Trent Neilson, Khang Le, Chintan Bhavsar, Yue Wang, Sharat Atluri, Gowri Irgam, Kiefer Wong, Da Yang, Raymond Steptoe, Sherry Y. Wu

Published in: Cancer Immunology, Immunotherapy | Issue 5/2024

Login to get access

Abstract

Cancer immunotherapy has seen significant success in the last decade for cancer management by enhancing endogenous cancer immunity. However, immunotherapies developed thus far have seen limited success in the majority of high-grade serous carcinoma (HGSC) ovarian cancer patients. This is largely due to the highly immunosuppressive tumour microenvironment of HGSC and late-stage identification. Thus, novel treatment interventions are needed to overcome this immunosuppression and complement existing immunotherapies. Here, we have identified through analysis of > 600 human HGSC tumours a critical role for Let-7i in modulating the tumoural immune network. Tumoural expression of Let-7i had high positive correlation with anti-cancer immune signatures in HGSC patients. Confirming this role, enforced Let-7i expression in murine HGSC tumours resulted in a significant decrease in tumour burden with a significant increase in tumour T cell numbers in tumours. In concert with the improved tumoural immunity, Let-7i treatment also significantly increased CD86 expression in antigen presenting cells (APCs) in the draining lymph nodes, indicating enhanced APC activity. Collectively, our findings highlight an important role of Let-7i in anti-tumour immunity and its potential use for inducing an anti-tumour effect in HGSC.
Appendix
Available only for authorised users
Literature
1.
Stewart C, Ralyea C, Lockwood S (2019) Ovarian cancer: an integrated review. Semin Oncol Nurs 35(2):151–156PubMed
2.
3.
Wu J et al (2018) Improved survival in ovarian cancer, with widening survival gaps of races and socioeconomic status: a period analysis, 1983–2012. J Cancer 9(19):3548–3556PubMedPubMedCentral
4.
Kuroki L, Guntupalli SR (2020) Treatment of epithelial ovarian cancer. BMJ 371:m3773PubMed
5.
Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM (2018) Advances in ovarian cancer therapy. Cancer Chemother Pharmacol 81(1):17–38PubMed
6.
Yang C, Xia BR, Zhang ZC, Zhang YJ, Lou G, Jin WL (2020) Immunotherapy for ovarian cancer: adjuvant, combination, and neoadjuvant. Front Immunol 11:577869PubMedPubMedCentral
7.
Baci D et al (2020) The ovarian cancer tumor immune microenvironment (TIME) as target for therapy: a focus on innate immunity cells as therapeutic effectors. Int J Mol Sci 21(9):3125PubMedPubMedCentral
8.
9.
10.
Kotecki N et al (2021) 983P Phase I dose escalation study in patients (pts) with advanced solid tumours receiving first-in-class BI 765063, a selective signal-regulatory protein a (SIRPa) inhibitor, in combination with ezabenlimab (BI 754091), a programmed cell death protein 1 (PD-1) inhibitor. Ann Oncol 32:S841–S842
11.
12.
Disis ML et al. (2016) Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity," ed: American Society of Clinical Oncology
13.
Varga A et al. (2015) Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study," ed: American Society of Clinical Oncology
14.
Hamanishi J et al (2015) Safety and antitumor activity of anti–PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 33(34):4015–4022PubMed
15.
Hinchcliff E et al (2018) Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials. Gynecol Oncol 151(3):407–413PubMedPubMedCentral
16.
Johnson RL, Cummings M, Thangavelu A, Theophilou G, de Jong D, Orsi NM (2021) Barriers to immunotherapy in ovarian cancer: metabolic, genomic, and immune perturbations in the tumour microenvironment. Cancers 13(24):6231PubMedPubMedCentral
17.
Leary A, Tan D, Ledermann J (2021) Immune checkpoint inhibitors in ovarian cancer: where do we stand? Ther Adv Med Oncol 13:17588359211039900PubMedPubMedCentral
18.
Raskov H, Orhan A, Christensen JP, Gögenur I (2021) Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. Br J Cancer 124(2):359–367PubMed
19.
Waldman AD, Fritz JM, Lenardo MJ (2020) A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 20(11):651–668PubMedPubMedCentral
20.
Zhang L et al (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348(3):203–213PubMed
21.
Yang C, Xia B-R, Zhang Z-C, Zhang Y-J, Lou G, Jin W-L (2020) Immunotherapy for ovarian cancer: adjuvant, combination, and neoadjuvant. Front Immunol Rev 11:577869
22.
Sato E et al (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci 102(51):18538–18543PubMedPubMedCentral
23.
Matsuzaki J et al (2010) Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A 107(17):7875–7880PubMedPubMedCentral
24.
Huang RY, Eppolito C, Lele S, Shrikant P, Matsuzaki J, Odunsi K (2015) LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. Oncotarget 6(29):27359–27377PubMedPubMedCentral
25.
Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39(1):1–10PubMed
26.
Zhang QF et al (2020) CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner. Theranostics 10(23):10619–10633PubMedPubMedCentral
27.
Yang M et al (2021) CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer. J Immunother Cancer 9(1):e001136PubMedPubMedCentral
28.
Miao YR et al (2021) Neutralization of PD-L2 is essential for overcoming immune checkpoint blockade resistance in ovarian cancer. Clin Cancer Res 27(15):4435–4448PubMedPubMedCentral
29.
30.
Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CMP (2013) Delivering the promise of miRNA cancer therapeutics. Drug Discovery Today 18(5):282–289PubMed
31.
32.
Vishnoi A, Rani S (2017) MiRNA biogenesis and regulation of diseases: an overview. Methods Mol Biol 1509:1–10PubMed
33.
To KKW, Fong W, Tong CWS, Wu M, Yan W, Cho WCS (2020) Advances in the discovery of microRNA-based anticancer therapeutics: latest tools and developments. Expert Opin Drug Discov 15(1):63–83PubMed
34.
Yang J et al (2014) MicroRNA-19a-3p inhibits breast cancer progression and metastasis by inducing macrophage polarization through downregulated expression of Fra-1 proto-oncogene. Oncogene 33(23):3014–3023PubMed
35.
Paladini L, Fabris L, Bottai G, Raschioni C, Calin GA, Santarpia L (2016) Targeting microRNAs as key modulators of tumor immune response. J Exp Clin Cancer Res 35(1):1–19
36.
Zhou J et al (2018) Exosomes Released from Tumor-Associated Macrophages Transfer miRNAs That Induce a Treg/Th17 Cell Imbalance in Epithelial Ovarian Cancer. Cancer Immunol Res 6(12):1578–1592PubMed
37.
Cichocki F et al (2011) Cutting edge: microRNA-181 promotes human NK cell development by regulating Notch signaling. J Immunol 187(12):6171–6175PubMed
38.
Pottoo FH et al (2021) miRNAs in the regulation of cancer immune response: effect of miRNAs on cancer immunotherapy. Cancers (Basel) 13(23):6145PubMed
39.
Gao F et al (2013) miR-9 modulates the expression of interferon-regulated genes and MHC class I molecules in human nasopharyngeal carcinoma cells. Biochem Biophys Res Commun 431(3):610–616PubMed
40.
Shao L et al (2021) MicroRNA-326 attenuates immune escape and prevents metastasis in lung adenocarcinoma by targeting PD-L1 and B7–H3. Cell Death Discovery 7(1):145PubMedPubMedCentral
41.
Xu Y et al (2020) MiRNA-340-5p mediates the functional and infiltrative promotion of tumor-infiltrating CD8(+) T lymphocytes in human diffuse large B cell lymphoma. J Exp Clin Cancer Res 39(1):238PubMedPubMedCentral
42.
Xie J, Liu M, Li Y, Nie Y, Mi Q, Zhao S (2014) Ovarian tumor-associated microRNA-20a decreases natural killer cell cytotoxicity by downregulating MICA/B expression. Cell Mol Immunol 11(5):495–502PubMedPubMedCentral
43.
Feng S, Sun H, Zhu W (2021) MiR-92 overexpression suppresses immune cell function in ovarian cancer via LATS2/YAP1/PD-L1 pathway. Clin Transl Oncol 23(3):450–458PubMed
44.
Vasaikar S, Straub P, Wang J, Zhang B (2018) LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res 46(D1):D956–D963PubMed
45.
46.
Wu SY, Putral LN, Liang M, Chang HI, Davies NM, McMillan NA (2009) Development of a novel method for formulating stable siRNA-loaded lipid particles for in vivo use. Pharm Res 26(3):512–522PubMed
47.
Chen R et al (2023) miR-146a inhibits ovarian tumor growth in vivo via targeting immunosuppressive neutrophils and enhancing CD8+ T cell infiltration. Mol Ther Oncolytics 31:100725PubMedPubMedCentral
48.
Veglia F, Sanseviero E, Gabrilovich DI (2021) Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol 21(8):485–498PubMedPubMedCentral
49.
Axelsson S, Magnuson A, Lange A, Alshamari A, Hörnquist EH, Hultgren O (2020) A combination of the activation marker CD86 and the immune checkpoint marker B and T lymphocyte attenuator (BTLA) indicates a putative permissive activation state of B cell subtypes in healthy blood donors independent of age and sex. BMC Immunol 21(1):1–9
50.
Wang LX, Zhang SX, Wu HJ, Rong XL, Guo J (2019) M2b macrophage polarization and its roles in diseases. J Leukocyte Biol 106(2):345–358PubMed
51.
Gilles ME, Slack FJ (2018) Let-7 microRNA as a potential therapeutic target with implications for immunotherapy. Expert Opin Ther Targets 22(11):929–939PubMedPubMedCentral
52.
Jiang S (2018) Recent findings regarding let-7 in immunity. Cancer Lett 434:130–131PubMed
53.
Geng L et al (2011) A let-7/Fas double-negative feedback loop regulates human colon carcinoma cells sensitivity to Fas-related apoptosis. Biochem Biophys Res Commun 408(3):494–499PubMed
54.
Wang S et al (2011) Let-7/miR-98 regulate Fas and Fas-mediated apoptosis. Genes Immun 12(2):149–154PubMed
55.
Chen Y et al (2019) LIN28/let-7/PD-L1 pathway as a target for cancer immunotherapy. Cancer Immunol Res 7(3):487–497PubMed
56.
Yu D et al (2019) The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation. Cell Commun Signal 17(1):173PubMedPubMedCentral
57.
Elkhadragy L, Chen M, Miller K, Yang MH, Long W (2017) A regulatory BMI1/let-7i/ERK3 pathway controls the motility of head and neck cancer cells. Mol Oncol 11(2):194–207PubMedPubMedCentral
58.
Qin MM et al (2019) let-7i inhibits proliferation and migration of bladder cancer cells by targeting HMGA1. BMC Urol 19(1):53PubMedPubMedCentral
59.
Chirshev E et al (2021) Let-7i reduces aggressive phenotype and induces BRCAness in ovarian cancer cells. Cancers (Basel) 13(18):4617PubMed
60.
Yang N et al (2008) MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 68(24):10307–10314PubMedPubMedCentral
61.
Wells A et al (2023) Let-7 enhances murine anti-tumor CD8 T cell responses by promoting memory and antagonizing terminal differentiation. Nat Commun 14(1):5585PubMedPubMedCentral
62.
63.
64.
Olden B, Cheng E, Cheng Y, Pun S (2019) Identifying key barriers in cationic polymer gene delivery to human T cells. Biomater Sci 7(3):789–797PubMedPubMedCentral
65.
Goode EL et al (2017) Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer. JAMA Oncol 3(12):e173290PubMedPubMedCentral
66.
Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G (2012) Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol 124(2):192–198PubMed
67.
68.
Pinzon-Charry A, Maxwell T, López JA (2005) Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol Cell Biol 83(5):451–461PubMed
69.
Xi X, Zhang L, Lu G, Gao X, Wei W, Ma G (2018) Lymph node-targeting nanovaccine through antigen-CpG self-assembly potentiates cytotoxic T cell activation. J Immunol Res 2018:3714960PubMedPubMedCentral
70.
Wang J et al (2016) microRNA-155 deficiency impairs dendritic cell function in breast cancer. Oncoimmunology 5(11):e1232223PubMedPubMedCentral
Metadata
Title
Let-7i enhances anti-tumour immunity and suppresses ovarian tumour growth
Authors
Andrew N. Wilkinson
Rui Chen
Elaina Coleborn
Trent Neilson
Khang Le
Chintan Bhavsar
Yue Wang
Sharat Atluri
Gowri Irgam
Kiefer Wong
Da Yang
Raymond Steptoe
Sherry Y. Wu
Publication date
01-05-2024
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 5/2024
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-024-03674-w

Other articles of this Issue 5/2024

Cancer Immunology, Immunotherapy 5/2024 Go to the issue

Research

Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours

Research

IL7 in combination with radiotherapy stimulates a memory T-cell response to improve outcomes in HNSCC models

Research

IL-2 promotes expansion and intratumoral accumulation of tumor infiltrating dendritic cells in pancreatic cancer

Research

PGRN inhibits CD8+T cell recruitment and promotes breast cancer progression by up-regulating ICAM-1 on TAM

Research

circFTO from M2 macrophage-derived small extracellular vesicles (sEV) enhances NSCLC malignancy by regulation miR-148a-3pPDK4 axis

Review

Bifidobacterium modulation of tumor immunotherapy and its mechanism
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits